ClinicalTrials.gg

Program

TNX-1500

A development code.

Its studies are led by Tonix Pharmaceuticals.

Furthest: phase 1, since Mar 10, 20261 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tonix Pharmaceuticals10 open or runningphase 1since Mar 10, 2026Mar 10, 2026none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 10, 2026First study: phase 1 study in Phase 1 First-in-human Study Involving Healthy SubjectsFirst studyNCT07473752 · 26 enrolled · United States

TargetBeta

CD40LG →read by rule
“The primary objective is to investigate the safety of TNX-1500, an FC-modified anti-CD154 mAb, in five kidney transplant recipients at 12 months.”study text, by rule · the study

Other programs on CD40LG

ProgramCompanyFurthest phaseStudies
frexalimabSanofiphase 311
dazodalibepruleAmgenphase 39
dapirolizumab pegolruleUCBphase 38
tegoprubartruleeledon-pharmaceuticalsphase 38
ravagalimabruleAbbViephase 24
OPT101ruleop-t-llcphase 24

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07473752Phase 1 First-in-human Study Involving Healthy Subjects · United States1CompletedFeb 22, 202426

How it is read

Names in the registry

  • “TNX-1500”, 1 entry

Codes read as this program: TNX1500.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.